Stefan Barghorn

USPTO Granted Patents = 17 (Patent Applications = 9)

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 6.3

ph-index = 5

Forward Citations = 80(Granted Patents)

Company Filing History:

13 out of 150

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Laboratories Corporation

Abbvie Deutschland Gmbh and Co Kg

patents

where one patent can have more than one assignee

Years Active: 2012-2020

Loading Chart...

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10538581 - Anti-Aβ globulomer 4D10 antibodies (2020-01-21),

2. 10323084 - Monoclonal antibodies against amyloid beta protein and uses thereof (2019-06-18),

3. 10208109 - Monoclonal antibodies against amyloid beta protein and uses thereof (2019-02-19),

4. 10047121 - Amyloid-beta binding proteins (2018-08-14),

5. 9951125 - Aβ conformer selective anti-Aβ globulomer monoclonal antibodies (2018-04-24),

6. 9822171 - Amyloid-beta binding proteins (2017-11-21),

7. 9540432 - Anti-Aβ globulomer 7C6 antibodies (2017-01-10),

8. 9394360 - Aβ conformer selective anti-Aβ globulomer monoclonal antibodies (2016-07-19),

9. 9359430 - Abeta conformer selective anti-Abeta globulomer monoclonal antibodies (2016-06-07),

10. 9062101 - Amyloid-beta binding proteins (2015-06-23),

11. 8987419 - Amyloid-beta binding proteins (2015-03-24),

12. 8895004 - Method for the treatment of amyloidoses (2014-11-25),

13. 8877190 - Aβ conformer selective anti-Aβ globulomer monoclonal antibodies (2014-11-04),

14. 8691224 - Anti-Aβ globulomer 5F7 antibodies (2014-04-08),

15. 8497072 - Amyloid-beta globulomer antibodies (2013-07-30),

Title: Inventor Spotlight: Stefan Barghorn

Introduction

Stefan Barghorn is a prominent inventor based in Mannheim, Germany, renowned for his contributions to the field of biomedical research. With an impressive portfolio of 17 patents, Barghorn has made significant strides in the development of innovative therapeutic solutions aimed at treating Alzheimer's disease and other neurodegenerative disorders.

Latest Patents

Among his latest creations, Barghorn has developed patents for Anti-Aβ globulomer 4D10 antibodies. This invention includes anti-Aβ globulomer antibodies, antigen-binding moieties, corresponding hybridomas, nucleic acids, vectors, host cells, and methods for production. The invention focuses on antibodies that exhibit a greater binding affinity to Aβ(20-42) globulomer when compared to Aβ(1-42) globulomer, making them crucial for therapeutic and diagnostic applications concerning Alzheimer's disease and other amyloidoses. Additionally, his work on monoclonal antibodies against amyloid beta protein, such as 8F5 and 8C5, aims to provide tools for the prevention, treatment, and diagnosis of Alzheimer's disease.

Career Highlights

Stefan Barghorn has held significant positions at leading companies in the pharmaceutical industry, including AbbVie Deutschland GmbH & Co. KG and AbbVie Inc. His work and research contributions have positioned him as a valuable asset in the field of antibody development and neurodegenerative disease research.

Collaborations

Throughout his career, Barghorn has collaborated with esteemed colleagues such as Heinz Hillen and Ulrich Ebert. These partnerships have further enhanced the scope and impact of his research, driving innovation within the industry.

Conclusion

Stefan Barghorn exemplifies the role of a dedicated inventor in the ever-evolving landscape of medical research. His pioneering patents and collaborative efforts underscore the importance of innovation in addressing complex health challenges, particularly in the realm of neurodegenerative diseases. As he continues to push the boundaries of what is possible through his inventions, Barghorn remains a significant figure in the pursuit of effective therapies for Alzheimer’s and related conditions.

This text is generated by artificial intelligence and may not be accurate.